BRIDGEWATER, N.J., Jan. 25, 2011 /PRNewswire/ — Aerocrine,
Inc., an innovative medical technology company focused on the
treatment of patients with inflamed airways, has selected R&J
Public Relations, LLC of Bridgewater, N.J., as its public relations
agency of record. R&J will conduct strategic public
relations for the Aerocrine brand; most immediately surrounding the
NIOX MINO®, the first and only hand-held device
available to measure exhaled nitric oxide (eNO) to aid in asthma
management in the United States.
For the first time ever, The NIOX MINO provides doctors the
ability to more effectively diagnose, monitor and optimize therapy
for individuals suffering from inflammatory airway diseases through
one easy-to-use device. This ground-breaking technology helps
eliminate the uncertainties that contribute to asthma morbidity and
mortality, including incorrect diagnosis, patient adherence issues,
and identifying those patients that will be responsive to
treatment.
“Our comprehensive experience and strong presence in the
healthcare market space combined with our aggressive and proactive
consumer and media relations practices will provide Aerocrine with
the leverage they need to elevate their innovative brand and
products,” said Scott Marioni, Executive Vice President of R&J
Public Relations. “R&J is confident that our strategic
public relations will significantly increase the awareness of the
Aerocrine brand and NIOX MINO while positioning eNO testing as a
standard for patients with asthmatic symptoms.”
The founders of Aerocrine originated from the Karolinska
Institute in Sweden where they first discovered the significant tie
between nitric oxide (NO) and inflammation. Aerocrine used
this discovery as a basis for creating products that assist in the
management and care of people afflicted with varying airway
inflammatory diseases.
R&J’s main objective is to promptly elevate Aero
‘/>”/>